RT Magazine

Regulatory Clearance: The Food and Drug Administration (FDA) granted 510(k) clearance to Medibyt for its CPETWise platform, clearing the way for commercialization across the US. Efficiency Gains: A 100-case study at the University of Washington showed that the software reduced cardiopulmonary exercise testing interpretation times by more than 50% with an average user satisfaction score of 4.5 out of 5.

Declining Burnout Rates: The percentage of pediatricians reporting burnout symptoms dropped from 46.2% in 2021 to 35.2% in 2025, according to a national survey analysis. Key Mitigating Factors: Researchers identified job changes, increased schedule flexibility, and decreased busyness in work environments as the three main factors linked to burnout reductions.

Federal Restructuring Concerns: The National Institutes of Health announced a proposed overhaul of clinical research programs at the National Institute of Allergy and Infectious Diseases with limited details and an abbreviated public comment window, according to medical leaders. Risks to Clinical Trials: Prolonged delays in federal funding renewals threaten active research networks and centers investigating HIV, tuberculosis, and viral hepatitis, placing study participants at risk.

According to the FDA, Draeger is aware of cases in which obvious cracks in the hose of the VentStar Resus Neo were detected by the users prior to use. If a cracked hose is used, the hose may fall off or leak resulting in restricted ventilation or delayed therapy which could lead to desaturation, hypoxia, or patient death, the FDA reports.

Expanded High-Risk Eligibility: The American Academy of Pediatrics updated its guidance to expand high-risk criteria for respiratory syncytial virus immunizations among children ages 8 through 19 months entering their second respiratory virus season, according to an AAP news release.

Novel Therapeutic Targets: Researchers identified an imbalance between two proteins, P2X7R and c-IAP2, that contributes to the progression of pulmonary arterial hypertension. Promising Preclinical Results: In animal models, blocking the inflammatory protein P2X7R with a targeted compound reduced key markers of the vascular disease.

Vaccine Recommendations: The Infectious Diseases Society of America strongly recommends that people with weakened immune systems receive vaccinations against COVID-19, influenza, and respiratory syncytial virus for the 2026-2027 season. Co-Administration Timing: Clinicians can administer all three seasonal respiratory immunizations during a single appointment, ideally scheduled prior to immunosuppressive procedures such as chemotherapy or organ transplants.

According to the FDA, GE HealthCare identified during a service update of Portrait Core Services software at a facility that some patients monitored on Portrait Mobile devices may be discharged (removed) from the Portrait monitoring system. In addition, all alarm settings may be reset to factory defaults following the updates. In this event, the device will not follow the alarm settings previously configured for each patient or care area, the FDA reports.

Regulatory Review: The FDA accepted a supplemental Biologics License Application (sBLA) for Enflonsia to protect high-risk children under 2 years of age during their second respiratory syncytial virus (RSV) season, setting a target action date of March 22, 2027. Expanded Patient Eligibility: If approved, vulnerable young children diagnosed with chronic lung disease (CLD), congenital heart disease (CHD), or qualifying preterm birth conditions would be eligible to receive a second-season dose.

Regulatory Review: The FDA has accepted a supplemental New Drug Application (sNDA) for nebulized Tyvaso (treprostinil) Inhalation Solution to treat idiopathic pulmonary fibrosis (IPF), with an anticipated decision date in late April 2027.